Total Payments
$2,912
2024 Payments
$298.86
Companies
16
Transactions
65
Medicare Patients
5,899
Medicare Billing
$384,264
Payment Breakdown by Category
Food & Beverage$2,762 (94.8%)
Other$150.00 (5.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,762 | 64 | 94.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $150.00 | 1 | 5.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch & Lomb, a division of Bausch Health US, LLC | $753.20 | 9 | $0 (2021) |
| Allergan, Inc. | $495.53 | 11 | $0 (2021) |
| Valeant Pharmaceuticals North America LLC | $409.13 | 7 | $0 (2017) |
| Aerie Pharmaceuticals, Inc. | $238.94 | 2 | $0 (2019) |
| Shire North American Group Inc | $208.03 | 6 | $0 (2018) |
| ABBVIE INC. | $167.74 | 5 | $0 (2024) |
| Kala Pharmaceuticals, Inc. | $139.14 | 8 | $0 (2021) |
| Bausch & Lomb Americas Inc. | $134.82 | 3 | $0 (2024) |
| RxSight Inc | $116.97 | 1 | $0 (2024) |
| TissueTech, Inc. | $77.24 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $298.86 | 6 | RxSight Inc ($116.97) |
| 2023 | $93.44 | 5 | Novartis Pharmaceuticals Corporation ($21.41) |
| 2022 | $134.94 | 3 | ABBVIE INC. ($134.94) |
| 2021 | $204.88 | 7 | Bausch & Lomb, a division of Bausch Health US, LLC ($101.87) |
| 2020 | $126.43 | 7 | Allergan, Inc. ($56.09) |
| 2019 | $624.60 | 13 | Bausch & Lomb, a division of Bausch Health US, LLC ($358.09) |
| 2018 | $704.63 | 12 | Bausch & Lomb, a division of Bausch Health US, LLC ($293.24) |
| 2017 | $724.52 | 12 | Valeant Pharmaceuticals North America LLC ($409.13) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 2 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/03/2020 | Allergan, Inc. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: GLAUCOMA | ||||||
| 03/03/2020 | TissueTech, Inc. | Prokera (Device), AmnioGraft, AmnioGuard | Food and Beverage | Cash or cash equivalent | $27.08 | General |
| Category: Medical Device (510K) | ||||||
| 02/11/2020 | TissueTech, Inc. | Prokera (Device), AmnioGraft, AmnioGuard | Food and Beverage | Cash or cash equivalent | $17.10 | General |
| Category: Medical Device (510K) | ||||||
| 12/04/2019 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug) | Food and Beverage | In-kind items and services | $4.76 | General |
| Category: OCULAR | ||||||
| 11/14/2019 | Aerie Pharmaceuticals, Inc. | Rhopressa (Drug), Rocklatan | Food and Beverage | In-kind items and services | $117.00 | General |
| Category: Glaucoma | ||||||
| 11/14/2019 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug) | Food and Beverage | In-kind items and services | $82.55 | General |
| Category: OCULAR | ||||||
| 09/25/2019 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $94.74 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/25/2019 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug) | Food and Beverage | In-kind items and services | $9.18 | General |
| Category: OCULAR | ||||||
| 09/25/2019 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug) | Food and Beverage | In-kind items and services | $4.23 | General |
| Category: OCULAR | ||||||
| 09/23/2019 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug) | Food and Beverage | In-kind items and services | $5.99 | General |
| Category: OCULAR | ||||||
| 09/23/2019 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug) | Food and Beverage | In-kind items and services | $2.17 | General |
| Category: OCULAR | ||||||
| 08/21/2019 | Bausch & Lomb, a division of Bausch Health US, LLC | LOTEMAX SM (Drug) | Food and Beverage | In-kind items and services | $95.66 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/18/2019 | Sun Pharmaceutical Industries Inc. | XELPROS (Drug) | Food and Beverage | Cash or cash equivalent | $23.95 | General |
| Category: Ophthalmology | ||||||
| 06/06/2019 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $87.43 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/25/2019 | Bausch & Lomb, a division of Bausch Health US, LLC | PROLENSA (Drug) | Food and Beverage | In-kind items and services | $80.26 | General |
| Category: OPHTHALMOLOGY | ||||||
| 01/17/2019 | TissueTech, Inc. | Prokera (Device), AmnioGraft, AmnioGuard | Food and Beverage | Cash or cash equivalent | $16.68 | General |
| Category: Medical Device (510K) | ||||||
| 11/19/2018 | TissueTech, Inc. | Prokera (Device), AmnioGraft, AmnioGuard | Food and Beverage | Cash or cash equivalent | $16.38 | General |
| Category: Medical Device (510K) | ||||||
| 09/19/2018 | Bausch & Lomb, a division of Bausch Health US, LLC | ZYLET (Drug) | Food and Beverage | In-kind items and services | $83.43 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/28/2018 | Allergan Inc. | LUMIGAN (Drug), COMBIGAN | Food and Beverage | In-kind items and services | $78.74 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/22/2018 | Aerie Pharmaceuticals, Inc. | Rhopressa (Drug) | Food and Beverage | In-kind items and services | $121.94 | General |
| Category: Ophthalmology | ||||||
| 07/19/2018 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/05/2018 | Shire North American Group Inc | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $6.97 | General |
| Category: OPTHALMICS | ||||||
| 06/11/2018 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug), ZYLET, BESIVANCE | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/18/2018 | Shire North American Group Inc | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $7.98 | General |
| Category: OPTHALMICS | ||||||
| 03/21/2018 | Shire North American Group Inc | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: OPTHALMICS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,158 | 1,238 | $191,455 | $75,312 |
| 2022 | 10 | 1,413 | 1,484 | $226,055 | $91,540 |
| 2021 | 10 | 1,544 | 1,621 | $241,025 | $102,719 |
| 2020 | 11 | 1,784 | 1,891 | $266,140 | $114,693 |
Total Patients
5,899
Total Services
6,234
Medicare Billing
$384,264
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Established patient complete exam of visual system | Office | 2023 | 456 | 464 | $81,200 | $37,154 | 45.8% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 211 | 260 | $39,000 | $15,416 | 39.5% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 120 | 120 | $30,000 | $10,757 | 35.9% |
| 92133 | Imaging of optic nerve | Office | 2023 | 127 | 127 | $12,700 | $3,099 | 24.4% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 54 | 54 | $9,180 | $2,371 | 25.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 32 | 55 | $4,400 | $2,093 | 47.6% |
| 92250 | Photography of the retina | Office | 2023 | 58 | 58 | $5,800 | $1,514 | 26.1% |
| 92134 | Imaging of retina | Office | 2023 | 42 | 42 | $4,200 | $1,154 | 27.5% |
| 92002 | New patient problem focused exam of visual system | Office | 2023 | 26 | 26 | $3,250 | $1,001 | 30.8% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 11 | 11 | $990.00 | $603.53 | 61.0% |
| 76514 | Ultrasound scan of cornea to determine thickness | Office | 2023 | 21 | 21 | $735.00 | $151.26 | 20.6% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 578 | 598 | $104,650 | $48,062 | 45.9% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 170 | 170 | $36,900 | $15,785 | 42.8% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 213 | 244 | $36,600 | $14,102 | 38.5% |
| 92133 | Imaging of optic nerve | Office | 2022 | 150 | 151 | $15,100 | $3,673 | 24.3% |
| 92250 | Photography of the retina | Office | 2022 | 100 | 101 | $10,100 | $2,569 | 25.4% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 60 | 60 | $10,200 | $2,352 | 23.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 42 | 59 | $3,780 | $2,303 | 60.9% |
| 92134 | Imaging of retina | Office | 2022 | 48 | 48 | $4,800 | $1,436 | 29.9% |
| 92002 | New patient problem focused exam of visual system | Office | 2022 | 23 | 23 | $2,875 | $1,050 | 36.5% |
| 76514 | Ultrasound scan of cornea to determine thickness | Office | 2022 | 29 | 30 | $1,050 | $207.59 | 19.8% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 654 | 676 | $118,300 | $56,373 | 47.7% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2021 | 152 | 152 | $30,400 | $15,161 | 49.9% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 214 | 247 | $37,050 | $14,723 | 39.7% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2021 | 156 | 158 | $15,800 | $4,151 | 26.3% |
About Dr. Stephen Hook, M.D
Dr. Stephen Hook, M.D is a Specialist healthcare provider based in Weslaco, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1669454682.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Hook, M.D has received a total of $2,912 in payments from pharmaceutical and medical device companies, with $298.86 received in 2024. These payments were reported across 65 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($2,762).
As a Medicare-enrolled provider, Hook has provided services to 5,899 Medicare beneficiaries, totaling 6,234 services with total Medicare billing of $384,264. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Ophthalmology
- Location Weslaco, TX
- Active Since 11/16/2005
- Last Updated 04/06/2017
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1669454682
Products in Payments
- VYZULTA (Drug) $512.98
- Rhopressa (Drug) $238.94
- LUMIGAN (Drug) $197.72
- PROLENSA (Drug) $180.26
- ZYLET (Drug) $172.07
- INVELTYS (Drug) $139.14
- XIIDRA (Drug) $136.22
- DURYSTA (Drug) $135.38
- BESIVANCE (Drug) $123.42
- RXSIGHT CONTACT LENS (Device) $116.97
- RESTASIS (Drug) $115.98
- MIEBO (Drug) $98.81
- LOTEMAX GEL (Drug) $97.07
- LOTEMAX SM (Drug) $95.66
- Prokera (Device) $77.24
- XELPROS (Drug) $23.95
- EYLEA HD (Biological) $20.01
- Syfovre (Drug) $18.15
- TEPEZZA (Biological) $13.83
- RESTASIS MULTIDOSE (Drug) $13.66
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.